243 related articles for article (PubMed ID: 32039686)
21. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M
Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
[TBL] [Abstract][Full Text] [Related]
22. Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics.
Gardner MR
Front Cell Infect Microbiol; 2020; 10():176. PubMed ID: 32391289
[TBL] [Abstract][Full Text] [Related]
23. Multiple roles for HIV broadly neutralizing antibodies.
Haynes BF; Burton DR; Mascola JR
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666399
[TBL] [Abstract][Full Text] [Related]
24. Antibody-mediated prevention and treatment of HIV-1 infection.
Gruell H; Klein F
Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
[TBL] [Abstract][Full Text] [Related]
25. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
[TBL] [Abstract][Full Text] [Related]
26. Broadly Neutralizing Antibodies for HIV Prevention.
Karuna ST; Corey L
Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
[TBL] [Abstract][Full Text] [Related]
27. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
Paneerselvam N; Khan A; Lawson BR
Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
[TBL] [Abstract][Full Text] [Related]
28. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
29. Broadly neutralizing antibodies for HIV-1 prevention and therapy.
Julg B; Barouch D
Semin Immunol; 2021 Jan; 51():101475. PubMed ID: 33858765
[TBL] [Abstract][Full Text] [Related]
30. Combination anti-HIV antibodies provide sustained virological suppression.
Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
[TBL] [Abstract][Full Text] [Related]
31. Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.
Umotoy JC; de Taeye SW
Front Immunol; 2021; 12():708806. PubMed ID: 34276704
[TBL] [Abstract][Full Text] [Related]
32. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
Girard MP; Picot V; Longuet C; Nabel GJ
Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
[TBL] [Abstract][Full Text] [Related]
33. Delivery platforms for broadly neutralizing antibodies.
Joshi LR; Gálvez NMS; Ghosh S; Weiner DB; Balazs AB
Curr Opin HIV AIDS; 2023 Jul; 18(4):191-208. PubMed ID: 37265268
[TBL] [Abstract][Full Text] [Related]
34. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Casazza JP; Cale EM; Narpala S; Yamshchikov GV; Coates EE; Hendel CS; Novik L; Holman LA; Widge AT; Apte P; Gordon I; Gaudinski MR; Conan-Cibotti M; Lin BC; Nason MC; Trofymenko O; Telscher S; Plummer SH; Wycuff D; Adams WC; Pandey JP; McDermott A; Roederer M; Sukienik AN; O'Dell S; Gall JG; Flach B; Terry TL; Choe M; Shi W; Chen X; Kaltovich F; Saunders KO; Stein JA; Doria-Rose NA; Schwartz RM; Balazs AB; Baltimore D; Nabel GJ; Koup RA; Graham BS; Ledgerwood JE; Mascola JR;
Nat Med; 2022 May; 28(5):1022-1030. PubMed ID: 35411076
[TBL] [Abstract][Full Text] [Related]
35. Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro.
Yao X; Wang Q; Han C; Nie J; Chang Y; Xu L; Wu B; Yan J; Chen Z; Kong W; Shi Y; Shan Y
Int J Nanomedicine; 2023; 18():4635-4645. PubMed ID: 37605734
[TBL] [Abstract][Full Text] [Related]
36. Broadly Neutralizing Antibodies against HIV: Back to Blood.
Dashti A; DeVico AL; Lewis GK; Sajadi MM
Trends Mol Med; 2019 Mar; 25(3):228-240. PubMed ID: 30792120
[TBL] [Abstract][Full Text] [Related]
37. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
Zhang Z; Li S; Gu Y; Xia N
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
[TBL] [Abstract][Full Text] [Related]
38. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
LaBranche CC; Henderson R; Hsu A; Behrens S; Chen X; Zhou T; Wiehe K; Saunders KO; Alam SM; Bonsignori M; Borgnia MJ; Sattentau QJ; Eaton A; Greene K; Gao H; Liao HX; Williams WB; Peacock J; Tang H; Perez LG; Edwards RJ; Kepler TB; Korber BT; Kwong PD; Mascola JR; Acharya P; Haynes BF; Montefiori DC
PLoS Pathog; 2019 Sep; 15(9):e1008026. PubMed ID: 31527908
[TBL] [Abstract][Full Text] [Related]
39. Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
Bharadwaj P; Riekofski C; Lin S; Seaman MS; Garber DA; Montefiori D; Sarzotti-Kelsoe M; Ackerman ME; Weiner JA
J Immunol Methods; 2020 Apr; 479():112764. PubMed ID: 32070674
[TBL] [Abstract][Full Text] [Related]
40. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities.
Liu Y; Cao W; Sun M; Li T
Emerg Microbes Infect; 2020; 9(1):194-206. PubMed ID: 31985356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
